Windward Bio Group Debuts on Nasdaq with $1.69 Billion Market Capitalization
Windward Bio Group AG (Nasdaq: WWB) has officially commenced trading on the Nasdaq Global Select Market following an initial public offering priced at $17.00 per share. The IPO raised approximately $225 million in gross proceeds, which includes a $50 million concurrent private placement from Sanofi. The company's market capitalization reached roughly $1.69 billion by the close of its first day of trading. Founded in 2024 by Dr. Luca Santarelli, Windward utilizes a 'NewCo' model to develop ultra-long-acting antibody medicines for respiratory and dermatologic diseases using assets licensed from Chinese biopharmaceutical firms. The company's lead candidate, WIN378, is currently undergoing Phase 2/3 clinical studies for asthma and Phase 2 for COPD, aiming for a twice-yearly dosing regimen that could significantly disrupt current treatment standards.
Tickers: $SNY
Topics: Biotechnology Clinical Stage Biotech IPO Nasdaq Listing
Read the full article at PR Newswire
Part of the story Windward Bio Group Debuts on Nasdaq with $1.69 Billion Market Capitalization (2 articles)